Vaccines and therapeutics for immunocompromised patients with COVID-19
Summary: The COVID-19 pandemic has disproportionately impacted immunocompromised patients. This diverse group is at increased risk for impaired vaccine responses, progression to severe disease, prolonged hospitalizations and deaths. At particular risk are people with deficiencies in lymphocyte numbe...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-05-01
|
| Series: | EClinicalMedicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589537023001426 |
| _version_ | 1797847273123610624 |
|---|---|
| author | Shmuel Shoham Carolina Batista Yanis Ben Amor Onder Ergonul Mazen Hassanain Peter Hotez Gagandeep Kang Jerome H. Kim Bhavna Lall Heidi J. Larson Denise Naniche Timothy Sheahan Nathalie Strub-Wourgaft Samba O. Sow Annelies Wilder-Smith Prashant Yadav Maria Elena Bottazzi |
| author_facet | Shmuel Shoham Carolina Batista Yanis Ben Amor Onder Ergonul Mazen Hassanain Peter Hotez Gagandeep Kang Jerome H. Kim Bhavna Lall Heidi J. Larson Denise Naniche Timothy Sheahan Nathalie Strub-Wourgaft Samba O. Sow Annelies Wilder-Smith Prashant Yadav Maria Elena Bottazzi |
| author_sort | Shmuel Shoham |
| collection | DOAJ |
| description | Summary: The COVID-19 pandemic has disproportionately impacted immunocompromised patients. This diverse group is at increased risk for impaired vaccine responses, progression to severe disease, prolonged hospitalizations and deaths. At particular risk are people with deficiencies in lymphocyte number or function such as transplant recipients and those with hematologic malignancies. Such patients’ immune responses to vaccination and infection are frequently impaired leaving them more vulnerable to prolonged high viral loads and severe complications of COVID-19. Those in turn, have implications for disease progression and persistence, development of immune escape variants and transmission of infection. Data to guide vaccination and treatment approaches in immunocompromised people are generally lacking and extrapolated from other populations. The large clinical trials leading to authorisation and approval of SARS-CoV-2 vaccines and therapeutics included very few immunocompromised participants. While experience is accumulating, studies focused on the special circumstances of immunocompromised patients are needed to inform prevention and treatment approaches. |
| first_indexed | 2024-04-09T18:08:40Z |
| format | Article |
| id | doaj.art-1eb50f891ae54256b5ca44e837ea4014 |
| institution | Directory Open Access Journal |
| issn | 2589-5370 |
| language | English |
| last_indexed | 2024-04-09T18:08:40Z |
| publishDate | 2023-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EClinicalMedicine |
| spelling | doaj.art-1eb50f891ae54256b5ca44e837ea40142023-04-14T04:19:44ZengElsevierEClinicalMedicine2589-53702023-05-0159101965Vaccines and therapeutics for immunocompromised patients with COVID-19Shmuel Shoham0Carolina Batista1Yanis Ben Amor2Onder Ergonul3Mazen Hassanain4Peter Hotez5Gagandeep Kang6Jerome H. Kim7Bhavna Lall8Heidi J. Larson9Denise Naniche10Timothy Sheahan11Nathalie Strub-Wourgaft12Samba O. Sow13Annelies Wilder-Smith14Prashant Yadav15Maria Elena Bottazzi16Johns Hopkins University School of Medicine, Baltimore, MD, USA; Corresponding author. 600 N. Wolfe Street Carnegie 346, Baltimore, MD 21287, USA.Médecins Sans Frontières, Rio de Janeiro, Brazil; Baraka Impact Finance, Geneva, SwitzerlandCenter for Sustainable Development, Columbia University, New York, NY, USAKoc University Research Center for Infectious Diseases, Istanbul, TurkeyCollege of Medicine, King Saud University, Riyadh, Saudi ArabiaTexas Children's Hospital Center for Vaccine Development, Baylor College of Medicine, Houston, TX, USAChristian Medical College, Vellore, IndiaInternational Vaccine Institute, Seoul, South KoreaUniversity of Houston Tilman J. Fertitta Family College of Medicine, Houston, TX, USALondon School of Hygiene & Tropical Medicine, London, UKISGlobal, Barcelona Institute for Global Health, Hospital Clinic, University of Barcelona, SpainUniversity of North Carolina, Gillings School of Global Public Health, Chapel Hill, NC, USAISGlobal, Barcelona Institute for Global Health, Hospital Clinic, University of Barcelona, Spain; Drugs for Neglected Diseases Initiative, Geneva, SwitzerlandCenter for Vaccine Development, Bamako, Mali; University of Maryland, MD, USALondon School of Hygiene & Tropical Medicine, London, UKCenter for Global Development, Washington, DC, USA; Harvard Medical School, Boston, MA, USA; Technology and Operations Management, INSEAD, Fontainebleau, FranceTexas Children's Hospital Center for Vaccine Development, Baylor College of Medicine, Houston, TX, USASummary: The COVID-19 pandemic has disproportionately impacted immunocompromised patients. This diverse group is at increased risk for impaired vaccine responses, progression to severe disease, prolonged hospitalizations and deaths. At particular risk are people with deficiencies in lymphocyte number or function such as transplant recipients and those with hematologic malignancies. Such patients’ immune responses to vaccination and infection are frequently impaired leaving them more vulnerable to prolonged high viral loads and severe complications of COVID-19. Those in turn, have implications for disease progression and persistence, development of immune escape variants and transmission of infection. Data to guide vaccination and treatment approaches in immunocompromised people are generally lacking and extrapolated from other populations. The large clinical trials leading to authorisation and approval of SARS-CoV-2 vaccines and therapeutics included very few immunocompromised participants. While experience is accumulating, studies focused on the special circumstances of immunocompromised patients are needed to inform prevention and treatment approaches.http://www.sciencedirect.com/science/article/pii/S2589537023001426COVID-19SARS-CoV-2ImmunocompromisedTransplantationMalignancy |
| spellingShingle | Shmuel Shoham Carolina Batista Yanis Ben Amor Onder Ergonul Mazen Hassanain Peter Hotez Gagandeep Kang Jerome H. Kim Bhavna Lall Heidi J. Larson Denise Naniche Timothy Sheahan Nathalie Strub-Wourgaft Samba O. Sow Annelies Wilder-Smith Prashant Yadav Maria Elena Bottazzi Vaccines and therapeutics for immunocompromised patients with COVID-19 EClinicalMedicine COVID-19 SARS-CoV-2 Immunocompromised Transplantation Malignancy |
| title | Vaccines and therapeutics for immunocompromised patients with COVID-19 |
| title_full | Vaccines and therapeutics for immunocompromised patients with COVID-19 |
| title_fullStr | Vaccines and therapeutics for immunocompromised patients with COVID-19 |
| title_full_unstemmed | Vaccines and therapeutics for immunocompromised patients with COVID-19 |
| title_short | Vaccines and therapeutics for immunocompromised patients with COVID-19 |
| title_sort | vaccines and therapeutics for immunocompromised patients with covid 19 |
| topic | COVID-19 SARS-CoV-2 Immunocompromised Transplantation Malignancy |
| url | http://www.sciencedirect.com/science/article/pii/S2589537023001426 |
| work_keys_str_mv | AT shmuelshoham vaccinesandtherapeuticsforimmunocompromisedpatientswithcovid19 AT carolinabatista vaccinesandtherapeuticsforimmunocompromisedpatientswithcovid19 AT yanisbenamor vaccinesandtherapeuticsforimmunocompromisedpatientswithcovid19 AT onderergonul vaccinesandtherapeuticsforimmunocompromisedpatientswithcovid19 AT mazenhassanain vaccinesandtherapeuticsforimmunocompromisedpatientswithcovid19 AT peterhotez vaccinesandtherapeuticsforimmunocompromisedpatientswithcovid19 AT gagandeepkang vaccinesandtherapeuticsforimmunocompromisedpatientswithcovid19 AT jeromehkim vaccinesandtherapeuticsforimmunocompromisedpatientswithcovid19 AT bhavnalall vaccinesandtherapeuticsforimmunocompromisedpatientswithcovid19 AT heidijlarson vaccinesandtherapeuticsforimmunocompromisedpatientswithcovid19 AT denisenaniche vaccinesandtherapeuticsforimmunocompromisedpatientswithcovid19 AT timothysheahan vaccinesandtherapeuticsforimmunocompromisedpatientswithcovid19 AT nathaliestrubwourgaft vaccinesandtherapeuticsforimmunocompromisedpatientswithcovid19 AT sambaosow vaccinesandtherapeuticsforimmunocompromisedpatientswithcovid19 AT annelieswildersmith vaccinesandtherapeuticsforimmunocompromisedpatientswithcovid19 AT prashantyadav vaccinesandtherapeuticsforimmunocompromisedpatientswithcovid19 AT mariaelenabottazzi vaccinesandtherapeuticsforimmunocompromisedpatientswithcovid19 |